Begins Coverage on Sorrento Therapeutics (NASDAQ:SRNE) began coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Free Report) in a report published on Saturday. The firm issued a hold rating on the biopharmaceutical company’s stock. Sorrento Therapeutics Price Performance NASDAQ:SRNE opened at $0.08 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.79 and a debt-to-equity […]

Leave a Reply

Your email address will not be published.

Previous post EchoStar (NASDAQ:SATS) Earns Buy Rating from Analysts at
Next post Gentherm (NASDAQ:THRM) PT Lowered to $70.00 at Craig Hallum